Edward W. Tate

The paper identifies a macrocyclic peptide binder, IMP2660, that disrupts RAB27A-effector interactions and enables crystallization of RAB27A without an effector, revealing its structural features.

This paper identifies SERINC5 as the primary target of retroviral antagonists and shows that a tri-cysteine motif in intracellular loop 4 is critical for its downregulation by HIV-1 Nef.

The paper shows that IMP-1700, a ciprofloxacin analogue, increases septum formation in S. aureus, enhancing daptomycin's effectiveness against resistant strains.

This paper develops the first cell-active covalent inhibitors of RAB27-effector interactions, showing enantioselectivity and improved potency over a previously reported toxic compound.

This paper identifies a phosphorylation-dependent mechanism that regulates splice variant-specific S-palmitoylation of Kv4.3, showing how phosphorylation at S538 primes palmitoylation at C546/547 and modulates channel function.

This study identifies RUVBL1/2 as a host ATPase essential for rhinovirus replication and shows that its inhibition effectively blocks viral replication without resistance development.

This study identifies prenylation as a regulator of cardiomyocyte proliferation through multiple targets, suggesting its potential for cardiac regeneration.

This study identifies RAS/PI3K pathway mutations as a biomarker for sensitivity to PARP/NAMPT inhibitor combination therapy in epithelial ovarian cancer.

This study enhances iNKT cell immunotherapy by combining optimized CAR endodomains with novel iNKT-specific engagers to improve anti-myeloma activity.

This study shows GBP1 is recruited to actin-rich pedestals formed by extracellular pathogens, promoting pyroptosis and IL-18 release, independent of LPS.

The paper identifies IMP-2380, a potent NorA inhibitor that enhances antibiotic activity by stabilizing the outward-open conformation of the efflux pump.

The paper introduces a chemical-genetic platform called SLIP to identify actionable sites on effector proteins for targeted protein degradation.

This paper introduces a high-throughput activity proteomics pipeline for discovering deubiquitinase inhibitors, identifying potent and selective inhibitors with minimal optimization.

This study uses APEX2 proteomics to map the spatiotemporal interactome of the luteinizing hormone receptor (LHR) and identifies novel interactors like RAP2B that modulate receptor signaling and trafficking.

This study designs and optimizes covalent VHL-targeted sulfonyl fluoride PROTACs that degrade BRD4 and androgen receptor without linker optimization.

The paper introduces a chemical genetic system to map ZDHHC-specific S-acylation substrates at the whole proteome level in intact cells.

The paper introduces a chemical tool, 6Yn-Pro, for identifying intracellular ADP-ribosylated proteins through metabolic labeling and chemical proteomics in HEK293T cells.

The paper analyzes cysteine accessibility in proteomic datasets to identify ligandable residues and proposes a framework for benchmarking cysteine profiling approaches.

The paper identifies a small molecule DUB probe, IMP-2373, that quantitatively engages multiple DUBs in live cells and demonstrates its use in studying DUB activity changes during MYC deregulation.

CRISPR-TAPE is a protein-centric gRNA design tool that enables targeting of specific residues or amino acid types, improving efficacy and reducing computational time.